
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics has strategically developed a robust pipeline that includes seven clinical and preclinical programs targeting novel mechanisms for a variety of neuropsychiatric and neurodegenerative disorders, which positions the company favorably in addressing significant unmet medical needs. Financial projections indicate potential US sales of $250 million in 2030 and $950 million by 2035, aligning with consensus estimates and demonstrating strong commercial potential for its lead asset, navacaprant, which is expected to achieve US sales of $750 million by 2028 and $3 billion at peak. Recent updates highlight the promising efficacy of NMRA-511 in Alzheimer's-related agitation and improved trial demographics, reinforcing optimism about its competitive advantage and strong market positioning in the treatment landscape.
Bears say
Neumora Therapeutics Inc. reported a significant net loss of $59.5 million in the fourth quarter of 2025, with research and development expenses totaling $44.7 million, highlighting ongoing financial strain as the company continues to advance its clinical programs. The negative outlook is further exacerbated by investor concerns regarding adverse event findings in the NMRA-215 program, raising doubts about its viability and future prospects. Additionally, the company's dependence on external financing to support its research initiatives until it becomes cash flow positive introduces substantial risks, including the potential for setbacks in clinical trials and increased market competition.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares